Production (Stage)
Theravance Biopharma, Inc.
TBPH
$9.30
-$0.19-2.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -17.95% | 11.18% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -17.95% | 11.18% | |||
| Cost of Revenue | -88.68% | 2.00% | |||
| Gross Profit | 53.94% | 22.38% | |||
| SG&A Expenses | -0.71% | 9.64% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.68% | 6.93% | |||
| Operating Income | -56.89% | 0.81% | |||
| Income Before Tax | -58.16% | 11.07% | |||
| Income Tax Expenses | -108.49% | 148.98% | |||
| Earnings from Continuing Operations | 12.55% | -22.28% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 12.55% | -22.28% | |||
| EBIT | -56.89% | 0.81% | |||
| EBITDA | -59.73% | 0.77% | |||
| EPS Basic | 13.24% | -21.63% | |||
| Normalized Basic EPS | -56.93% | -4.71% | |||
| EPS Diluted | 13.24% | -21.63% | |||
| Normalized Diluted EPS | -56.93% | -4.71% | |||
| Average Basic Shares Outstanding | 0.81% | 0.55% | |||
| Average Diluted Shares Outstanding | 0.81% | 0.55% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||